U.S. Stocks See Further Downside As Fed Minutes Highlight Uncertainty
https://www.rttnews.com/story.aspx?Id=3414515
Jan 03, 2024 - After kicking off the new year on a downbeat note, stocks saw further downside over the course of the trading session on Wednesday. The major averages all fell on the day, with the tech-heavy Nasdaq closing lower for the fourth consecutive session. The continued weakness on Wall Street partly reflected concerns investors have become too optimistic about the near-term interest rate cuts.
0
U.S. Stocks May See Further Downside As Interest Rate Uncertainty Resurfaces
https://www.rttnews.com/story.aspx?Id=3414443
Jan 03, 2024 - After starting the new year on a downbeat note, stocks may see continued weakness in early trading on Wednesday. Concerns investors have become too optimistic about the likelihood of near-term interest rate cuts may weigh on the markets ahead of the release of the minutes of the Federal Reserve's latest monetary policy meeting later in the day.
0
'Big Short' investor Steve Eisman worries 'everybody is coming into the year feeling too good,' sees room for disappointment
https://www.cnbc.com/2024/01/02/big-shorts-steve-eisman-worries-investors-are-too-bullish-in-2024.html
Jan 02, 2024 - Steve Eisman of Neuberger Berman sees little tolerance for things going wrong. He warns the Federal Reserve will likely cut rates fewer times than expected.
0
AST SpaceMobile soars after seeing fundraising close this month
https://seekingalpha.com/news/4051767-ast-spacemobile-soars-after-seeing-fundraising-close-this-month?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
Jan 02, 2024 - AST SpaceMobile (ASTS) shares surge 6.4% after announcing plans to close strategic investment and report initial ground infrastructure orders.
0
Wall Street Analysts See a 197.7% Upside in C4 Therapeutics, Inc. (CCCC): Can the Stock Really Move This High?
https://www.zacks.com/stock/news/2204156/wall-street-analysts-see-a-197-7-upside-in-c4-therapeutics-inc-cccc-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2204156
Jan 01, 2024 - The mean of analysts' price targets for C4 Therapeutics, Inc. (CCCC) points to a 197.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
0
Wall Street Analysts See Realty Income Corp. (O) as a Buy: Should You Invest?
https://www.zacks.com/stock/news/2204094/wall-street-analysts-see-realty-income-corp-o-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2204094
Jan 01, 2024 - Based on the average brokerage recommendation (ABR), Realty Income Corp. (O) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
0
Spirits revenue in U.S. to rise 3% in 2024 as consumers see affordable luxury
https://seekingalpha.com/news/4051334-spirits-revenue-us-rise-3-2024-consumers-see-affordable-luxury?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
Dec 31, 2023 - The U.S. spirits industry is expected to see a 3% revenue increase in 2024, driven by the popularity of vodka and tequila. Read more here.
0
Shopping on New Year's Day 2024? From Costco to Walmart, see what stores are open and closed
https://www.startribune.com/shopping-on-new-years-day-2024-from-costco-to-walmart-see-what-stores-are-open-and-closed/600331438/
Dec 30, 2023 - give or take some fresh resolutions.
0
ConocoPhillips (COP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
https://www.zacks.com/stock/news/2203911/conocophillips-cop-sees-a-more-significant-dip-than-broader-market-some-facts-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2203911
Dec 29, 2023 - ConocoPhillips (COP) closed the most recent trading day at $116.07, moving -0.37% from the previous trading session.
0
Boston Sci sees Farapulse PFA receiving FDA approval in Q1
https://seekingalpha.com/news/4051087-boston-sci-sees-farapulse-pfa-receiving-fda-approval-in-q1?source=feed_sector_healthcare
Dec 28, 2023 - Boston Scientific (BSX) sees its Farapulse PFA System receiving FDA approval for atrial fibrillation, or AF, in Q1 2024 and has initiated a study of the system for persistent AF.
0